Mediwound (NASDAQ:MDWD) had its price target dropped by investment analysts at Oppenheimer from $15.00 to $7.00 in a research note issued to investors on Wednesday, The Fly reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target would suggest a potential upside of 132.56% from the company’s current price.
A number of other equities analysts also recently issued reports on the stock. ValuEngine upgraded shares of Mediwound from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. HC Wainwright began coverage on shares of Mediwound in a research note on Monday, August 5th. They set a “buy” rating and a $5.50 price objective on the stock. Finally, Zacks Investment Research upgraded shares of Mediwound from a “sell” rating to a “hold” rating in a research note on Friday, July 12th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Mediwound presently has an average rating of “Buy” and an average price target of $7.25.
MDWD stock traded down $0.16 during mid-day trading on Wednesday, reaching $3.01. The company had a trading volume of 38,900 shares, compared to its average volume of 190,528. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.99 and a quick ratio of 3.79. The stock has a market cap of $86.70 million, a P/E ratio of -6.14 and a beta of 0.49. The business has a 50 day moving average of $3.24. Mediwound has a 12 month low of $2.55 and a 12 month high of $6.75.
Mediwound (NASDAQ:MDWD) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.03. Mediwound had a negative net margin of 18.43% and a negative return on equity of 383.19%. The business had revenue of $20.75 million for the quarter, compared to the consensus estimate of $7.03 million. Equities analysts anticipate that Mediwound will post -0.59 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of MDWD. Meitav Dash Investments Ltd. raised its holdings in shares of Mediwound by 0.6% in the first quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock worth $2,993,000 after buying an additional 3,536 shares during the last quarter. ARK Investment Management LLC purchased a new position in shares of Mediwound during the second quarter worth $325,000. Millennium Management LLC raised its holdings in shares of Mediwound by 33.2% during the fourth quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock worth $278,000 after purchasing an additional 17,048 shares during the last quarter. Menta Capital LLC raised its holdings in shares of Mediwound by 200.2% during the first quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 29,686 shares during the last quarter. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of Mediwound by 33.5% during the second quarter. Oppenheimer & Co. Inc. now owns 43,800 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 11,000 shares during the last quarter. 31.16% of the stock is owned by institutional investors.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Further Reading: What is the market perform rating?
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.